Abstract

Tissues in the anterior segment of the eye are particular vulnerable to oxidative stress. To minimise oxidative stress, ocular tissues utilise a range of antioxidant defence systems which include nonenzymatic and enzymatic antioxidants in combination with repair and chaperone systems. However, as we age our antioxidant defence systems are overwhelmed resulting in increased oxidative stress and damage to tissues of the eye and the onset of various ocular pathologies such as corneal opacities, lens cataracts, and glaucoma. While it is well established that nonenzymatic antioxidants such as ascorbic acid and glutathione are important in protecting ocular tissues from oxidative stress, less is known about the delivery mechanisms used to accumulate these endogenous antioxidants in the different tissues of the eye. This review aims to summarise what is currently known about the antioxidant transport pathways in the anterior eye and how a deeper understanding of these transport systems with respect to ocular physiology could be used to increase antioxidant levels and delay the onset of eye diseases.

1. Introduction

We are constantly exposed to oxidative stress through our environment, by products of metabolism and lifestyle factors. The positioning of tissues in the anterior segment of the eye makes them particularly susceptible to oxidative stress. Oxidative stress stimulates the production of unstable and highly reactive oxygen species (ROS) that are responsible for cellular damage. To combat the ubiquitous presence of ROS, ocular tissues have evolved diverse antioxidant defence systems to prevent permanent and lasting ROS-mediated tissue damage. However, as we age, prooxidants overwhelm the antioxidant defences resulting in oxidative stress and damage to tissues of the eye associated with the development of ocular pathologies such as corneal opacities, cataracts, and glaucoma. It is therefore no surprise that the therapeutic potential of natural and nutraceutical antioxidants in treating eye diseases is widely explored within vision research [1]. However, epidemiological studies into the use of such supplements have produced mixed results (reviewed by [2]). The uncertainty associated with the efficacy of antioxidant supplements is compounded by a lack of fundamental knowledge on the molecular pathways via which antioxidants accumulate in these tissues as well as a lack of understanding of basic physiological principles that underpin ocular function. Understanding and appreciating the integrated nature of antioxidant delivery and antioxidant metabolism pathways of the different tissues of the anterior eye with respect to ocular physiology are required for the design of antioxidant targeted therapies that will be effective in delaying the onset of corneal oedema, cataracts, and glaucoma—conditions for which preventive approaches do not currently exist.

2. Anatomy and Physiology of Ocular Tissues in the Anterior Segment

The cornea is the primary barrier between the environment and ocular tissues. It is responsible for ~75% of the total refractive power of the eye, a function owing to its transparency and unique curvature. The outermost layer of the cornea is the epithelium and is constantly exposed to mechanical stress, microbial invasion, external chemical insults, and UV radiation. The middle stromal layer accounts for nearly 90% of corneal thickness and plays a key role in maintaining corneal transparency, strength, and curvature [35]. It consists of nerve fibres and keratocytes which produce and maintain components of the extracellular matrix such as collagen fibres and hydrated proteoglycans. The precise arrangement and concentration of components within the stroma not only bestow incredible tensile strength to the cornea but also limit light scattering. Any irregularities in this arrangement can lead to stromal oedema and loss of transparency. The endothelium is a monolayer of squamous hexagonal cells and directly interfaces with the aqueous humour. A primary function of the corneal endothelium is to maintain stromal hydration by use of endothelial pumps that actively transport ions across the membrane to generate an osmotic gradient that draws fluid away from the stroma and into the aqueous humour. The endothelium is extremely susceptible to injury, inflicted either by mechanical trauma during intraocular surgery, inflammatory responses, or an increase in intraocular pressure [5]. Unfortunately, it does not have the capacity for regeneration, and when cells are lost or lose functionality, they cannot be mitotically replaced resulting in stromal oedema.

The primary function of the lens is to focus light onto the retina. To achieve this, the lens is composed of an ordered arrangement of crystalline fibre cells which are derived from equatorial epithelial cells which exit the cell cycle and embark upon a differentiation process that produces extensive cellular elongation, the loss of cellular organelles and nuclei, and the expression of fibre-specific proteins [6]. Since this process continues throughout life, a gradient of fibre cells at different stages of differentiation is established around an internalised nucleus of mature, anucleate fibre cells [7]. Because there is little protein turnover in the lens nucleus, proteins in this region are particularly susceptible to oxidative damage. Since the lens is avascular, it has been hypothesised that a specialised lens microcirculation system operates to deliver nutrients and antioxidants and to remove waste products [8, 9]. The working model suggests that ionic currents, carried primarily by Na+, enter the lens predominantly via both poles along the extracellular spaces between fibre cells. The current then propagates across fibre cell membranes and flows towards the lens surface via an intracellular pathway mediated by gap junctions which connect all fibre cells. The influx of ions is accompanied by the convection of water, oxygen, and solutes to the deeper-lying fibre cells, while the efflux of ions facilitates the removal of fibre cell waste products. Consistent with this model, ion channels and transporters have been found in distinct fibre cell membrane domains that allow the uptake and export of solutes [7]. Regional distribution of connexin protein isoforms, which comprise gap junctions, has also been noted and may cater to the metabolic needs of specific lens regions [10]. It is theorised that disruption or inadequate functioning of the circulatory system, especially pertaining to delivery of antioxidants, could lead to cataract formation [11].

The main function of the trabecular meshwork (TM) is to provide a site through which aqueous humour can leave the eye [12]. The TM is a mesh consisting of connective tissue progressively acquiring greater resistance to aqueous outflow towards Schlemm’s canal (Figure 1(d)). The inner layer facing the anterior chamber is known as the uveal meshwork [13] and contains intertrabecular spaces that range up to 100 μm, offering negligible resistance to flow [4]. Further inward is the corneoscleral meshwork which exists as several flat sheets of trabeculae that are irregularly perforated [4, 14]. In this layer, the intertrabecular space ranges between 5 and 20 μm, providing a greater resistance to aqueous outflow. The outermost portion of the TM is the cribriform or juxtacanalicular meshwork which lies immediately adjacent to the endothelial cells lining Schlemm’s canal [15]. This layer consists of sheets of loosely arranged TM cells that are embedded in a dense extracellular matrix composed of many types of fine collagen fibrils and proteoglycans [13, 14]. Due to the much narrower intercellular spaces, this layer provides the most resistance to aqueous humour flow in the TM [4, 1315]. The TM thus regulates the resistance to aqueous humour outflow which is a crucial determinant of intraocular pressure (IOP) [4, 15]. An increase in the resistance of aqueous flow through the TM and therefore impaired drainage function result in elevated IOP and primary open angle glaucoma.

A common feature of these tissues is their avascular nature and their dependence on either tears or aqueous humour for their supply of glucose, amino acids, and antioxidants. The vast literature on exogenous antioxidant supplementation and the mixed findings from epidemiological studies on ocular health are not surprising given that (1) these compounds are unable to reach their target tissue via the circulatory system and (2) transporter proteins must be expressed in the cornea and lens to specifically accumulate these exogenous molecules into ocular cells. Current research is focused on designing more appropriate systems for drug delivery to the front of the eye with a great deal of attention paid towards improving ocular drug bioavailability and towards the development of noninvasive sustained drug release for anterior segment disorder. In comparison, less is known about the molecular identity of endogenous antioxidant transporter systems in the anterior eye and how these transport systems could be utilized to enhance the availability of antioxidants to specific regions within ocular tissues.

3. Antioxidant Systems of the Anterior Eye

The two key antioxidants of the eye are ascorbic acid (vitamin C) and glutathione (GSH), which are present at 1 mM [16] and 2 μM [17], respectively, in the human aqueous humour. While all tissues contain high levels of these antioxidants, the corneal epithelium has the highest concentration of ascorbic acid [18] and the lens has the highest concentration of GSH, indicating that these two antioxidants are particularly important in protecting these tissues from oxidative stress.

3.1. Ascorbic Acid

Many mammals have the ability to synthesise ascorbic acid de novo; however humans and a few other species, including Wistar rats [19], lack the enzyme L-gulonolactone oxidase necessary for ascorbic acid synthesis [20] and, therefore, rely purely on dietary intake of ascorbic acid [21]. The high concentrations of ascorbic acid in the aqueous humour, together with its ability to absorb UV light, have led to its referral as a physiological “sunscreen” [22], preventing the penetration of UV light and protecting tissues from photo-induced oxidative damage [23]. As a scavenging species, ascorbic acid is oxidised by ROS in a two-step process which detoxifies or stabilises hydroxyl and superoxide anion radicals [24]. Ascorbic acid is first converted to ascorbate free radicals, which can be recycled back to ascorbic acid by ascorbate free radical (AFR) reductase [25] and then to dehydroascorbate (DHA). DHA is then reduced to regenerate ascorbic acid pools either via glutathione-dependent enzymes or nonenzymatically using low molecular weight antioxidants such as GSH or cysteine. This ensures that low levels of DHA are maintained. In the absence of ascorbic acid-DHA cycling, DHA undergoes irreversible degradation to diketogulonic acid which is implicated in modifying and crosslinking lens proteins [26, 27]. Ascorbic acid is known to protect the reducing powers of other antioxidants such as α-tocopherol (vitamin E) by rescuing α-tocopheryl radicals in membranes [28]. As a reducing agent ascorbic acid may also act as a prooxidant by reducing metal ions, which leads to the generation of free radicals through the Fenton reaction [29]. Aside from its reducing properties, ascorbic acid is also essential for collagen synthesis and has anti-inflammatory properties, preventing extensive tissue damage in the eye [30, 31].

3.2. Glutathione

Glutathione can also be obtained from the diet but is primarily synthesised de novo from the amino acids cysteine, glutamate, and glycine via the sequential actions of γ-glutamylsynthetase and GSH synthetase. GSH is a powerful antioxidant with multiple functions in the eye. It protects protein thiol groups by affording protection against ROS, is necessary for the functioning of several glutathione-dependent antioxidant enzymes that neutralize ROS, and is responsible for drug detoxification [32]. GSH also mediates the recycling of DHA to ascorbic acid further increasing the antioxidant capacity of the eye [33, 34]. GSH levels are maintained by an active glutathione redox cycle that ensures a high GSH to GSSG (oxidized GSH) ratio. To achieve this, the redox cycle utilizes the reciprocal actions of two enzymes: glutathione peroxidase (GPX) whose action involves the oxidation of GSH to GSSG and glutathione reductase (GR) which converts GSSG back to GSH.

3.3. Enzymatic Antioxidants

In the anterior chamber of the eye, superoxide dismutase (SOD), catalase, and glutathione-related enzymes act in conjunction with each other to play a critical role in regulating the production of ROS and precluding any tissue damage. While ascorbic acid is the main antioxidant in the aqueous humour, it is not as efficient in detoxifying ROS as antioxidant enzymes such as SOD [35]. SOD activity is essential for regulating the production of superoxide anions—it catalyses the conversion of superoxide anions to H2O2 which in turn can be converted to water and oxygen by catalase [36]. Catalase activity is very important because, unlike the superoxide radical, H2O2 is an uncharged molecule that can easily cross membranes. GSH-related enzymes rely on the presence of glutathione to exert their antioxidant. Glutathione reductase (GR) is a NADPH-dependent enzyme that facilitates the conversion of oxidised glutathione (GSSG) to reduced glutathione (GSH), thus maintaining the pool of total glutathione in its reduced and active form. In concert with GR, glutathione peroxidase (GPX) uses GSH to detoxify organic hydroperoxides and hydrogen peroxide resulting in the formation of GSSG and water.

4. Mechanisms for Accumulating Ascorbic Acid in the Anterior Eye

The positioning of the cornea means that it is constantly exposed to high amounts of UV radiation. To scavenge ROS and protect itself from light-induced damage, the corneal epithelium contains high concentrations of ascorbic acid which far exceed concentrations found in other ocular tissues [18, 23]. The corneal epithelium most likely sources ascorbic acid from tear fluids and accumulates it via the sodium-dependent vitamin C transporter 2 (SVCT2) which has been shown to be expressed in rabbit corneal epithelial cells [37] (Figure 1(a)). To a considerably lesser extent, ascorbic acid in the corneal epithelium may also be accumulated via passive diffusion from the endothelium and stroma [38]. On the other hand, the corneal endothelium preferentially takes up DHA from the aqueous humour via the facilitative glucose transporter, GLUT1, the DHA then being immediately reduced to ascorbic acid [39] (Figure 1(a)). It has also been reported to stimulate the active transport of chloride across the endothelium [40] which has been shown to significantly increase wound healing rate [41]. Ascorbic acid has been shown to be protective to endothelial cells since addition of ascorbic acid to the irrigation solution during phacoemulsification significantly reduces the amount of endothelial cell loss [42].

In the lens, ascorbic acid has many roles including prevention of membrane lipid peroxidation and the protection of lens cation pumps [19, 43]. Accumulation of ascorbic acid in the lens (~1 mM) [44] occurs by transport of both ascorbic acid and DHA (Figure 1(b)). Although DHA in the aqueous humour constitutes only about 10% of total reduced ascorbic acid, it is DHA which appears to be preferentially transported into the lens [45]. This accumulation is mediated by facilitative glucose transporters (GLUT1/3) followed by its rapid conversion to ascorbic acid [46]. DHA is known to be toxic to the lens [47] and has been linked to the formation of senile [34, 48, 49] and diabetic cataract. In human diabetes patients and animal models of diabetes leading to cataract formation, ascorbic acid levels in the lens are decreased and DHA levels are increased [50, 51]. The lens is also capable of direct ascorbic acid uptake; however this accumulation appears to be restricted to the lens epithelium [52, 53]. In a human lens epithelial cell line, ascorbic acid uptake is mediated by SVCT2, which is also upregulated in response to oxidative stress [54]. A recent study suggests that, in addition to SVCT2 and GLUTs, the water channel AQP0 may also be involved in the transport of ascorbic acid since its expression was increased in diabetic rats and upon ascorbic acid treatment [55]. Mouse fibroblasts overexpressing AQP0 displayed increased uptake of ascorbic acid and appear to aid its export, suggesting a bidirectional channel which could maintain ascorbic acid levels in lens fibres [56].

In cultured bovine trabecular meshwork cells, physiological ascorbic acid levels have been shown to promote cell growth, glycosaminoglycan production [57], and stimulation of fibronectin, laminin, and collagen type I production which are crucial for basal lamina assembly [58, 59]. Ascorbic acid may also play a protective role in minimising oxidative stress and damage to the trabecular meshwork [60]. Such damage would affect aqueous humour outflow and increase intraocular pressure, a risk factor for the development of glaucoma. Indeed, studies analysing the ascorbic acid levels in the aqueous humour of glaucoma patients and nonglaucoma/cataract controls have shown significantly lower levels of ascorbic acid in glaucoma patients [61]. Currently, the molecular identities of transporters involved in uptake of ascorbic acid/DHA into the TM are unknown.

5. Mechanisms for Accumulating Glutathione in the Anterior Eye

While overall GSH concentrations in the cornea are lower relative to ascorbic acid concentrations, GSH plays a major role in corneal defence. It is involved in maintaining the barrier function of the corneal endothelium, controlling normal hydration levels, protecting cell membrane integrity, and degrading xenobiotics agents. In other tissues, GSH levels are maintained via a combination of GSH uptake, de novo synthesis from its precursor amino acids, GSH regeneration from GSSG by glutathione reductase, and GSH efflux. Surprisingly, there is limited information regarding the molecular pathways involved in maintaining GSH homeostasis in the cornea. Previous work has investigated GSH uptake by measuring 35S-GSH in the different layers of the cornea and found that the highest concentrations of 35S-GSH were detected in the stroma [62]. However, the transporters responsible for this GSH uptake in the cornea remain unknown. In addition, studies also suggest that GSSG rather than GSH may be better at preserving endothelial barrier function since it was found that the barrier function of the rabbit corneal endothelium was better maintained by supplementing the perfusion solution with 0.3 mM GSSG rather than 0.6 mM GSH [63]. This suggests that the corneal endothelium can rapidly turn over endothelial GSH by glutathione reductase and that the endothelium is able to preferentially accumulate GSSG [64, 65], although it is similarly unclear what transport mechanism is involved.

A recent study into potential pathways for uptake of precursor amino acids utilized for GSH synthesis colocalized the Na+-dependent glutamate transporters (EAATs) and the Na+-independent cystine/glutamate exchanger ( ) in the human corneal epithelium [66] (Figure 1(a)). This was followed up by a more recent study, in which it has been shown that , its substrate cysteine, and the rate limiting enzyme for GSH synthesis, γ-glutamylcysteine synthetase (γ-GCS), were also localised to the rat corneal epithelium [67]. In tissues such as the brain, these two systems have been demonstrated to work together to mediate cysteine uptake for GSH synthesis [68]. The system mediates the Na+-independent exchange of extracellular cystine (the oxidised form of cysteine) for intracellular glutamate, while the EAATs maintain the outwardly directed glutamate concentration gradient required for glutamate exchange with cystine [69]. Upon intracellular accumulation, cystine is rapidly reduced to cysteine where it can be incorporated into proteins and/or used in the synthesis of GSH. These findings, together with others, show that the system also operates in the cornea and that GSH synthesis is most likely restricted to the epithelial layer and not the endothelium.

The liver and kidney are major sites of GSH uptake, synthesis, and export and can therefore offer potential clues as to the molecular pathways that may operate in the cornea to maintain GSH levels. Two members of the organic anion transporter (OAT1 and OAT3) and the sodium dicarboxylate 3 transporter (NaDC3) have been shown to be involved in GSH uptake across the renal basolateral membrane [70]. NaDC3 is a secondary active transporter which couples the uptake of GSH to that of Na+ ions. OAT1 and OAT3 couple the outwardly directed gradient of 2-oxoglutarate with GSH uptake. Two GSH export mechanisms have been identified in the liver—the multidrug resistance associated proteins (MRPs) 1, 2, 4, and 5 and the organic anion transporting polypeptide (Oatp) 1 and 2, although only the rat Oatps and not human OATP appear to contribute to GSH release [7072]. The MRPs mediate efflux of organic anions such as GSH at the expense of cellular ATP while the Oatps catalyses the uptake of organic anions in exchange for GSH [73]. MRPs also mediate export of oxidised GSH (GSSG), as well as glutathione-S-conjugates and the subsequent elimination of xenobiotics [70].

Of the three putative GSH uptake transporters, only OAT3 and NaDC3 are expressed at the transcript and protein level in the rat cornea [67]. Subsequent immunohistochemical analysis has revealed that both OAT3 and NaDC3 colocalise to the endothelium but are absent from the epithelium (Figure 1(a)). Of the putative GSH efflux transporters only MRP4 and MRP5 were detected at the transcript and protein level, and localisation studies revealed these transporters to be present in the epithelial layers only (Figure 1(a)). These findings demonstrate the corneal epithelium and endothelium to exhibit differences in GSH uptake, synthesis, and efflux pathways. The corneal epithelium appears to be the region where GSH synthesis and GSH efflux occurs. In the endothelium, however, GSH accumulation is likely to be predominantly via direct uptake of GSH from the aqueous humour.

Among ocular tissues, the lens has the highest concentrations of GSH (6–10 mM) [74]. In the lens, GSH synthesis is restricted to the metabolically active epithelial and cortical layers, resulting in a gradient of GSH—with the highest levels being present in the central epithelium and cortical fibre cells and lowest in the lens core [75, 76]. In the rat lens, GSH precursor amino acid transporters have been reported to be involved in the uptake of cysteine, glycine, and glutamate for GSH synthesis (Figure 1(b)). We showed that in the outer cortex and EAAT4/5 colocalize indicating that these transporters may work together to accumulate cysteine for GSH synthesis [77]. On the other hand, appears to switch its glutamate recycling partner to alanine-serine-cysteine transporter (ASCT2) which transports glutamate at low pH, which coincides with the acidic environment in the lens core [78]. Since these mature anucleate fibre cells are not capable of protein/GSH synthesis, it has been proposed that and ASCT2 may work to accumulate cysteine where it can act as a low molecular mass antioxidant in this highly compact region. The glycine transporters, GLYT1 and GLYT2, were both shown to be localised to the lens cortex indicating a role in glycine uptake in cortical fibre cells (Figure 1(b)). Interestingly, GLYT2 was also expressed in the lens core. This indicates that GLYT2 may be responsible for the accumulation of glycine in the centre of the lens where it may act as an antiglycation agent to protect against protein modifications associated with age-related nuclear cataract. Furthermore, work in the authors’ laboratories has identified the GSH uptake transporters OAT3 and NaDC3 but not OAT1 in the rat lens (Figure 1(b)). Immunolocalisation experiments show that NaDC3 is localized to the cytoplasm of epithelial and cortical fibre cells while OAT3 was strongly localized to the apical-apical interface indicating OAT3 to be the most likely candidate to mediate GSH uptake in this region [79].

In the excised bovine trabecular meshwork, glutathione is reported at a concentration of 0.40 μmol/g tissue wet weight [80]. While there is no direct evidence for glutathione involvement in regulating aqueous humour outflow, it does protect against the deleterious effects of H2O2, which is known to cause tissue damage that could compromise outflow [60, 80]. In patients that exhibit open-angle glaucoma, the glutathione content of the trabecular meshwork was found to decrease with progressive deterioration of the disease, suggesting a correlation between disease pathogenesis and glutathione content [4]. A recent study has identified the presence of MRP4 in the trabecular meshwork; however its involvement in GSH transport has not been investigated [81]. Thus, the mechanisms utilised by the trabecular meshwork to accumulate GSH remain unclear.

6. An Integrated View of Ocular Physiology and Antioxidant Delivery

Ocular tissues are continuously subjected to a variety of physical, chemical, and environmental insults that generate ROS and create an oxidative environment in the eye. The tissues in the anterior segment of the eye, particularly the cornea, lens, and trabecular meshwork, bear the brunt of this oxidative stress due in part to their positioning in the eye and the avascular nature of these tissues. Unsurprisingly these tissues utilise similar antioxidant defence systems (Figure 1) which aid in regulating ROS production and maintaining overall ocular health. The aqueous humour is a key source of antioxidants to tissues in the front of the eye. The lens epithelium and the corneal endothelium contain transport and/or recycling pathways for accumulating antioxidants from the aqueous humour. However, to maintain overall antioxidant balance within the anterior eye, it is likely that these tissues possess intertissue signalling pathways that enable crosstalk between individual tissues.

The ciliary body provides the aqueous humour with antioxidants, nutrients, and amino acids. However, in contrast to ion transport and fluid transport [82], little is known about the transport pathways used by the ciliary epithelium to mediate antioxidant, nutrient, and amino acid secretion. The ciliary body is believed to actively concentrate ascorbic acid from the plasma, via SVCT2 located in the pigmented epithelial (PE) cell layer [21, 83, 84] or uptake of DHA via GLUT1 located in both the PE and NPE (nonpigmented epithelial) layers [85], followed by DHA recycling [33] and then secretion of ascorbic acid into the aqueous humour [86] (Figure 1(c)). The ciliary body also possesses antioxidant enzyme activity for catalase [87], glutathione reductase [88], and glutathione peroxidase [89, 90]. Among the anterior ocular tissues, the ciliary body has one of the highest SOD activities [91, 92] and, in addition, is thought to release GPX into the aqueous humour to aid in removal of H2O2 [93]. Recently, the contribution of the ciliary epithelium to GSH levels in the aqueous humour has been examined by mapping GSH metabolism and transport pathways in the rat ciliary body [94, 95]. Both the PE and NPE cell layers are capable of accumulating precursor amino acids for GSH synthesis, but only the NPE cells appear to be involved in the direct uptake of precursor amino acids from the stroma (Figure 1(c)). The location of GSH efflux transporters to the basolateral membrane of the NPE indicates that these cells can mediate GSH secretion into the aqueous humour [95, 96]. GSH can then be used directly by anterior tissues of the eye such as the lens and cornea to protect against oxidative stress. Collectively, these studies demonstrate the ciliary body to play an important role in providing the aqueous humour with a source of antioxidants and antioxidant enzymes that can be utilised to protect anterior ocular tissues from oxidative stress.

7. Therapeutic Potential

With increasing age, a decrease in antioxidants and/or antioxidant enzyme activity occurs, leading to progressive tissue damage and ocular pathologies. A large number of studies have explored the use of antioxidants (both endogenous and exogenous) in treating eye diseases. In comparison, only a few studies have investigated the molecular processes by which antioxidants accumulate in ocular tissues. For example, the use of thiol antioxidants and their derivatives, such as cysteine, glutathione, N-acetylcysteine (NAC), and more recently N-acetylcysteine amide (NACA), has been examined in providing protection from age-related nuclear cataracts [97102]. The use of NAC and NACA has been found to be more effective against various oxidative stress-related disorders because of their ability to permeate cell membranes and bypass transporter mediated cysteine uptake. However, whether these cysteine analogues can act directly as antioxidants in the lens nucleus is unlikely since they would be rapidly incorporated into GSH in the cortex and this would limit their diffusion-dependent delivery to the lens centre. Rather a transporter-mediated pathway such as the system is likely to be more effective in accumulating cystine/cysteine directly into nuclear fibre cells. Moving ahead, identification of other transporters used to accumulate endogenous antioxidants in ocular tissues could highlight alternative pathways that could then be targeted to increase uptake and elevate antioxidant levels.

While we have described the actions of antioxidant compounds and enzymes that directly minimize oxidative stress, we have omitted enzymatic repair systems (such as thioltransferases (TTase) and thioredoxins (Trx) [103]) found in ocular tissues for the repair of oxidatively damaged and cross-linked proteins. These have been comprehensively reviewed elsewhere [104]. Yan and colleagues demonstrated that thioredoxin and thioredoxin reductase, which participate in the repair of oxidatively damaged lens protein and enzymes in combination with the chaperone protein alpha crystallin, could revive glutathione reductase activity in human cataractous lenses [105].

Despite the presence of immense antioxidant capacity, with age, ocular tissues can readily succumb to ROS-mediated damage. Thus, it is important to understand the transport systems and repair pathways responsible for accumulating and maintaining these antioxidants in ocular tissues, so that more targeted therapies can be developed and made successful.